UPSHER-SMITH ADDS DICYCLOMINE HYDROCHLORIDE CAPSULES, USP TO ITS PRODUCT LINE
16 May 2023
Drug Approval
MAPLE GROVE, Minn., May 16, 2023 /PRNewswire/ -- – Upsher-Smith Laboratories, LLC (Upsher-Smith) today announced the launch of Dicyclomine Hydrochloride Capsules, USP 10 mg. The company now offers the product in tablet and capsule forms.
The dicyclomine hydrochloride capsule market had U.S. sales of approximately $36.8 million for the 12 months ending March 2023 according to IQVIA.
Product Information
For questions about ordering, please call Upsher-Smith at 1-800-654-2299.
Please refer to full Prescribing Information for Dicyclomine Hydrochloride Capsules, USP here. You can also call 1-888-650-3789 to obtain a copy of the full Prescribing Information. You are encouraged to report suspected adverse reactions to Upsher-Smith Laboratories, LLC at 1-855-899-9180 or to the FDA by visiting .
About Upsher-Smith
Upsher-Smith Laboratories, LLC is a trusted U.S. pharmaceutical company that strives to improve the health and lives of patients through an unwavering commitment to high-quality products and sustainable growth. The company brings brands and generics to a wide array of customers, always backed by its attentive level of service, strong industry relationships, and dedication to uninterrupted supply. For more information, visit .
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
-Targets
-Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.